ANAPEN JUNIOR SOLUTION

Ország: Kanada

Nyelv: angol

Forrás: Health Canada

Aktív összetevők:

EPINEPHRINE

Beszerezhető a:

ENDO VENTURES LTD.

ATC-kód:

C01CA24

INN (nemzetközi neve):

EPINEPHRINE

Adagolás:

0.15MG

Gyógyszerészeti forma:

SOLUTION

Összetétel:

EPINEPHRINE 0.15MG

Az alkalmazás módja:

INTRAMUSCULAR

db csomag:

0.3ML

Recept típusa:

Ethical

Terápiás terület:

ALPHA-AND BETA-ADRENERGIC AGONISTS

Termék összefoglaló:

Active ingredient group (AIG) number: 0104871011; AHFS:

Engedélyezési státusz:

APPROVED

Engedély dátuma:

2022-01-14

Termékjellemzők

_ _
Page 1 of 21
ANAPEN and ANAPEN JUNIOR
Prescribing Information
ANAPEN
®
Sterile epinephrine injection Mfr. Std.
Unidose 0.3 mg epinephrine auto-injector
ANAPEN
® JUNIOR
Sterile epinephrine injection Mfr. Std.
Unidose 0.15 mg epinephrine auto-injector
Catecholamine / Sympatomimetic
Endo Ventures Ltd.
Date of Revision:
First Floor, Minerva House,
January 14, 2022
Simmonscourt Road, Ballsbridge
Dublin 4, Ireland
Importer/Distributor:
Paladin Labs Inc.
100 Alexis Nihon Blvd, Suite 600
St-Laurent, H4M 2P2
Quebec, Canada
Submission Control No: 255336
®
Registered trademark of Bioprojet UK Ltd.
_ _
Page 2 of 21
ANAPEN and ANAPEN JUNIOR
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
5
WARNINGS AND PRECAUTIONS
.................................................................................
5
ADVERSE REACTIONS
...................................................................................................
8
DRUG INTERACTIONS
...................................................................................................
9
DOSAGE AND ADMINISTRATION
...............................................................................
9
OVERDOSAGE
...............................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 11
STORAGE AND STABILITY
.........................................................................................
12
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 12
PART II: SCIENTIFIC INFORMATION
.......................................